Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Autor: Banerjee, S., Oza, A.M., Birrer, M.J., Hamilton, E.P., Hasan, J., Leary, A., Moore, K.N., Mackowiak-Matejczyk, B., Pikiel, J., Ray-Coquard, I., Trask, P., Lin, K., Schuth, E., Vaze, A., Choi, Y., Marsters, J.C., Maslyar, D.J., Lemahieu, V., Wang, Y., Humke, E.W., Liu, J.F. ^*

Publikováno v: In Annals of Oncology April 2018 29(4):917-923

518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation

Autor: Oza, A.M., Lisyanskaya, A.S., Fedenko, A.A., de Melo, A.C., Shparik, Y., Bondarenko, I., Colombo, N., Lorusso, D., Cibula, D., Póka, R.L., Oaknin, A., Safra, T., Maćkowiak-Matejczyk, B., Ma, L., Thomas, D., Lin, K.K., McLachlan, K., Goble, S., Kristeleit, R.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S780-S780

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

Autor: Kristeleit R; Department of Oncology, UCL Cancer Institute, University College London, London, UK. Electronic address: rebecca.kristeleit@gstt.nhs.uk., Lisyanskaya A; Oncogynecological Department, Saint Petersburg City Oncological Dispensary, Saint Petersburg, Russia., Fedenko A; Department of Chemotherapy, N N Blokhin Russian Cancer Research Center, Moscow, Russia., Dvorkin M; Omsk Region Clinical Oncologic Dispensary, Omsk, Russia., de Melo AC; Division of Clinical Research and Technological Development, Instituto Nacional de Câncer - Hospital do Câncer II, Rio de Janeiro, Brazil., Shparyk Y; Department of Chemotherapy, Lviv Regional Oncology Dispensary, Lviv, Ukraine., Rakhmatullina I; Department of Chemotherapy, Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan, Ufa, Russia; Department of Oncology with IAPE Oncology and Pathologic Anatomy Course, Bashkir State Medical University, Ufa, Russia., Bondarenko I; Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine., Colombo N; Gynecologic Cancer Program, University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Milan, Italy., Svintsitskiy V; Department of Oncogynecology, National Cancer Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine., Biela L; Clinical Research Center, Instituto de Oncologia do Parana (IOP), Curitiba, Brazil., Nechaeva M; Department of Chemotherapy, Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russia., Lorusso D; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy., Scambia G; Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy., Cibula D; Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic., Póka R; Department of Obstetrics and Gynecology, Clinical Center, University of Debrecen, Debrecen, Hungary., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Safra T; Department of Oncology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Mackowiak-Matejczyk B; Bialostockie Centrum Onkologii im Marii Sklodowskiej-Curie, Białystok, Poland., Ma L; Rocky Mountain Cancer Centers, Lakewood, CO, USA., Thomas D; Clinical Operations, Clovis Oncology, Boulder, CO, USA., Lin KK; Molecular Diagnostics, Clovis Oncology, Boulder, CO, USA., McLachlan K; Clinical Development, Clovis Oncology, Boulder, CO, USA., Goble S; Biostatistics, Clovis Oncology, Boulder, CO, USA., Oza AM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2022 Apr; Vol. 23 (4), pp. 465-478. Date of Electronic Publication: 2022 Mar 14.

IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance.

Autor: Reddy, Suprataptha U.¹ (AUTHOR) suprataptha.ummadi22@my.stjohns.edu, Sadia, Fatema Zohra¹ (AUTHOR), Vancura, Ales¹ (AUTHOR), Vancurova, Ivana¹ (AUTHOR) vancuroi@stjohns.edu

Publikováno v: Cancers. Aug2024, Vol. 16 Issue 15, p2676. 23p.

Ascites Fluid Interleukin-8 Level as a Predictor of Survival in Patients with Ovarian Cancer: Analytical Research-Cohort Research.

Autor: FAHMI, Moh Nailul¹ nailul.fahmi@mail.ugm.ac.id, KURNIAWAN, Patricia Alika²

Publikováno v: Journal of Clinical Obstetrics & Gynecology. 2024, Vol. 34 Issue 3, p98-105. 8p.